Neuromyelitis optica spectrum disorder (NMOSD) is a rare immune-mediated astrocytopathy associated with recurrent inflammatory attacks of the central nervous system and substantial morbidity if not diagnosed and treated promptly. This Executive Summary presents the key recommendations and summary of the supporting evidence from the Malaysian Consensus Statements for the Diagnosis and Management of NMOSD.

A modified Delphi methodology involving a multidisciplinary panel from public and private healthcare institutions was employed. Consensus statements were developed through structured discussions, iterative review, and three rounds of anonymous voting with a predefined agreement threshold of 75%. Subsequent refinement included supplementary considerations for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and double-seronegative NMOSD. International evidence and guideline recommendations were contextualised to reflect Malaysian clinical practice and healthcare resource considerations.
The final consensus comprised 36 statements across 9 domains, with an additional 3 supplementary statements relating to MOGAD and double-seronegative NMOSD. It addressed diagnosis, treatment selection, relapse management, biologic monitoring, vaccination, and biologic use in special populations. The recommendations emphasise the continued use of established diagnostic criteria and highlight the central role of aquaporin-4 immunoglobulin G (AQP4-IgG) serostatus for diagnosis and therapeutic decisions. Approved biologic therapies are supported for AQP4-IgG–seropositive NMOSD, with guidance provided for the use of off-label immunosuppression in resource-variable settings.

These Malaysian consensus statements provide a practical and locally relevant framework to support more consistent and evidence-based NMOSD care. The full consensus document and detailed evidence summaries are available online via the Malaysian Society of Neurosciences website.

1. Abboud, H., Petrak, A., Mealy, M., Sreih, A. G., & Levy, M. (2016). Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Multiple Sclerosis Journal, 22(2), 185–192. https://doi.org/10.1177/1352458515581438
2. Abboud, H., Salazar-Camelo, A., George, N., Planchon, S. M., & Cohen, J. A. (2022). Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology, 269(4), 1786–1801. https://doi.org/10.1007/s00415-021-10774-6
3. Akaishi, T., Takahashi, T., Fujihara, K., Misu, T., Abe, M., Ishii, T., Aoki, M., & Nakashima, I. (2021). Early treatment initiation with oral prednisolone for relapse prevention alleviates depression and fatigue in Aquaporin-4-positive neuromyelitis optica spectrum disorder. Frontiers in Neurology, 12, Article 608149. https://doi.org/10.3389/fneur.2021.608149
4. Akaishi, T., & Misu, T. (2024). Anti-aquaporin-4 antibody (AQP4-IgG) and anti-myelin oligodendrocyte glycoprotein antibody (MOG-IgG) in the cerebrospinal fluid. Neural Regeneration Research, 19(5), 949–950. https://doi.org/10.4103/1673-5374.385282
5. Aljarallah, S., AlThobaiti, A., Abulaban, A., Al Najashi, K., Al-Asmi, A., Al-Otaibi, M. S., & Cupler, E. J. (2025). Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review. Multiple Sclerosis and Related Disorders, 104, Article 106847. https://doi.org/10.1016/j.msard.2025.106847
6. Apóstolos-Pereira, S. L. D., Damasceno, A., Piccolo, A. C., Adoni, T., Alvarenga, M. P., Bichuetti, D. B., Fragoso, Y. D., Gomes, S., Kaimen-Maciel, D. R., Marchiori, P. E., Papais-Alvarenga, R. M., Vasconcelos, C. C. F., Von Glehn, F., & Callegaro, D. (2025). 2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children. Arquivos de Neuro-Psiquiatria, 83(11), 1–21. https://doi.org/10.1051/arnp/20250011
7. Aungsumart, S., Youngkong, S., Dejthevaporn, C., & Srinonprasert, V. (2023). Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis. Frontiers in Neurology, 14, Article 1166490. https://doi.org/10.3389/fneur.2023.1166490
8. Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., Chitnis, T., Yamamura, T., Pellegrini, M. N., Palace, J., & Reindl, M. (2023). Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. The Lancet Neurology, 22(3), 268–282. https://doi.org/10.1016/S1474-4422(22)00431-8
9. Barreras, P., Vasileiou, E., Filippatou, A., Fitzgerald, K. C., Pardo, C. A., Newsome, S. D., & Levy, M. (2022). Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology, 99(22), e2504–e2516. https://doi.org/10.1212/WNL.0000000000201183
10. Bennett, J. L., Fujihara, K., Saiz, A., Yamamura, T., Kim, H. J., Palace, J., & Traboulsee, A. (2025). Long-term efficacy and safety of satralizumab in patients with neuromyelitis optica spectrum disorder from the SAkuraMoon open-label extension study. Neurology: Neuroimmunology & Neuroinflammation, 12(5), Article e200450. https://doi.org/10.1212/NXI.0000000000200450
11. Bichuetti, D. B., Boulos, F. C., Shinosaki, J. S., Falcão, A. B., & Oliveira, E. M. L. (2012). Treatment of neuromyelitis optica with intravenous immunoglobulin: Report of 8 patients. Neurology, 78(1 Suppl), P04.141. https://doi.org/10.1212/WNL.78.1_MeetingAbstracts.P04.141
12. Bichuetti, D. B., Perin, M. M. M., Souza, N. A., & Oliveira, E. M. L. (2019). Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Multiple Sclerosis Journal, 25(8), 1150–1161. https://doi.org/10.1177/1352458518783347
13. Bilodeau, P. A., Wruble Clark, M., Ganguly, A., Boroojerdi, B., & Levy, M. (2026). Real-world efficacy and safety of neuromyelitis optica spectrum disorder disease-modifying treatments. Neurology: Neuroimmunology & Neuroinflammation, 13(2), Article e200536. https://doi.org/10.1212/NXI.0000000000200536
14. Borisow, N., Mori, M., Kuwabara, S., Scheel, M., & Paul, F. (2018). Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Frontiers in Neurology, 9, Article 888. https://doi.org/10.3389/fneur.2018.00888
15. Breu, M., Glatter, S., Höftberger, R., Kornek, B., & Seidl, R. (2019). Two cases of pediatric AQP4-antibody positive neuromyelitis optica spectrum disorder successfully treated with tocilizumab. Neuropediatrics, 50(3), 193–196. https://doi.org/10.1055/s-0039-1683979
16. Briggs, F. B. S., & Shaia, J. (2024). Prevalence of neuromyelitis optica spectrum disorder in the United States. Multiple Sclerosis Journal, 30(3), 316–324. https://doi.org/10.1177/13524585231221150
17. Cacciaguerra, L., & Flanagan, E. P. (2024). Updates in NMOSD and MOGAD diagnosis and treatment: A tale of two central nervous system autoimmune inflammatory disorders. Neurologic Clinics, 42(1), 77–114. https://doi.org/10.1016/j.ncl.2023.06.009
18. Carnero Contentti, E., Rotstein, D., Okuda, D. T., & Wingerchuk, D. M. (2025). How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 31(1), 8–22. https://doi.org/10.1177/13524585241289123
19. Carreón Guarnizo, E., Hernández Clares, R., Castillo Triviño, T., & Meca Lallana, J. E. (2022). Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurología (English Edition), 37(3), 178–183. https://doi.org/10.1016/j.nrleng.2019.03.027
20. Carroll, W. M., & Grisold, W. (2024). World Federation of Neurology Needs Registry Survey, 2021. Journal of the Neurological Sciences, 465, Article 123124. https://doi.org/10.1016/j.jns.2024.123124
21. Carta, S., Calvo, A. C., Armangué, T., Sepúlveda, M., Sola-Valls, N., Alba-Rovira, R., Mariño-Pérez, L., Ruiz-García, R., Bioque, M., & Saiz, A. (2023). Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: A retrospective multicenter study. Neurology, 100(11), e1095–e1108. https://doi.org/10.1212/WNL.0000000000201662
22. Centers for Disease Control and Prevention. (2026). Clinical guidance for managing meningococcal disease risk in patients receiving complement inhibitor therapy. U.S. Department of Health and Human Services. https://www.cdc.gov/meningococcal/hcp/clinical-guidance/complement-inhibitor.html
23. Chew, E., Rotstein, D. L., & Viswanathan, S. (2025). Navigating a paradigm shift in the treatment of CNS demyelinating diseases in a middle-income country. Multiple Sclerosis and Related Disorders, 100, Article 106544. https://doi.org/10.1016/j.msard.2025.106544
24. Chico-Garcia, J. L., de la Prida, M. M., Lago, A. B., & Martinez-Gines, C. (2026). Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: A retrospective study. Therapeutic Advances in Neurological Disorders, 19, 1–14. https://doi.org/10.1177/17562864251234567
25. Cobo-Calvo, Á. (2025, September 24–26). 2025 diagnostic criteria for NMOSD: Implications for double seronegative cases [Conference presentation]. ECTRIMS Congress. https://www.neurologylive.com/view/evolving-approaches-seronegative-nmosd-new-diagnostic-criteria-lvaro-cobo-calvo
26. Connelly-Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Witt, V., Zantek, N. D., & Dunbar, N. M. (2023). Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the Writing Committee of the American Society for Apheresis: The ninth special issue. Journal of Clinical Apheresis, 38(2), 77–278. https://doi.org/10.1002/jca.22043
27. Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., Green, A. J., Aktas, O., Hartung, H. P., Lublin, F. D., Drappa, J., Barron, G., Madani, S., Ratchford, J. N., & N-MOmentum Study Group. (2019). Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. The Lancet, 394(10206), 1352–1363. https://doi.org/10.1016/S0140-6736(19)31817-3
28. Demuth, S., & Collongues, N. (2025). Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies. Revue Neurologique (Paris), 181(1–2), 42–51. https://doi.org/10.1016/j.neurol.2024.10.005
29. Diamond, I. R., Grant, R. C., Feldman, B. M., Pencharz, P. B., Ling, S. C., Moore, A. M., & Wales, P. W. (2014). Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. Journal of Clinical Epidemiology, 67(4), 401–409. https://doi.org/10.1016/j.jclinepi.2013.12.002
30. Digala, L., Katyal, N., Narula, N., & Govindarajan, R. (2021). Eculizumab in the treatment of aquaporin-4 seronegative neuromyelitis optica spectrum disorder: A case report. Frontiers in Neurology, 12, Article 660741. https://doi.org/10.3389/fneur.2021.660741
31. Dugue, A. (2025). The 2024 revised McDonald criteria: AAN 2025 highlights. Neurology AMJ, 2(1), 26–29.
32. Ellwardt, E. E., Ellwardt, L., Bittner, S., & Zipp, F. (2018). Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurology: Neuroimmunology & Neuroinflammation, 5(4), Article e463. https://doi.org/10.1212/NXI.0000000000000463
33. Elsone, L., Panicker, J., Mutch, K., Boggild, M., Appleton, R., & Jacob, A. (2014). Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: Experience in 10 patients. Multiple Sclerosis Journal, 20(4), 501–504. https://doi.org/10.1177/1352458513495938
34. Fujihara, K. (2019). Neuromyelitis optica spectrum disorders: Still evolving and broadening. Current Opinion in Neurology, 32(3), 385–394. https://doi.org/10.1097/WCO.0000000000000694
35. Haramati, A., Rechtman, A., Zveik, O., Vaknin-Dembinsky, A., & Lotan, I. (2022). IL-6 as a marker for NMOSD disease activity. Journal of Neuroimmunology, 370, Article 577925. https://doi.org/10.1016/j.jneuroim.2022.577925
36. Hayes, M. T. G., Adam, R. J., McCombe, P. A., & Henderson, R. D. (2024). Long-term efficacy and safety of rituximab in the treatment of neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal—Experimental, Translational and Clinical, 10(2), Article 20552173241257876. https://doi.org/10.1177/20552173241257876
37. Hjerthen, I. G., Hacker, C. T., Pandit, L., & Marignier, R. (2024). Underemployment, work hour reduction, and income loss: A global, multi-centered, cohort study of neuromyelitis optica. Multiple Sclerosis and Related Disorders, 92, Article 105998. https://doi.org/10.1016/j.msard.2024.105998
38. Holian, A. H., & Weinshenker, B. G. (2025). Emerging role of targeted monoclonal antibodies in neuromyelitis optica spectrum disorders. BioDrugs, 39(4), 573–589. https://doi.org/10.1007/s40259-025-00680-8
39. Isobe, N., Oda, T., Yamaguchi, T., & Yamasaki, R. (2025). Incidence and risk factors for serious infections in patients with neuromyelitis optica spectrum disorder: A claims database study in Japan. Neurology and Therapy, 14(5), 1993–2009. https://doi.org/10.1007/s40120-025-00620-1
40. Jacob, A., Mahmoud, A., Eldweik, L., & Levy, M. (2025). Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: A case report. BMJ Neurology Open, 7(2), Article e001286. https://doi.org/10.1136/bmjno-2025-001286
41. Jarius, S., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Berthele, A., Giglhuber, K., Havla, J., Hellwig, K., Hümmert, M. W., Kleiter, I., Klotz, L., Korporal-Kuhnke, M., Krumbholz, M., Kümpfel, T., Ringelstein, M., Ruprecht, K., Senel, M., Stellmann, J. P., Trebst, C., … Wildemann, B. (2023). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)—Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology, 270(7), 3341–3368. https://doi.org/10.1007/s00415-023-11634-0
42. Jarius, S., Franciotta, D., Paul, F., Ruprecht, K., Bergamaschi, R., Rommer, P. S., Reuss, R., Probst, C., Komorowski, L., France, J., Minten, B., Fritzler, M. J., & Wildemann, B. (2010). Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: Frequency, origin, and diagnostic relevance. Journal of Neuroinflammation, 7, Article 52. https://doi.org/10.1186/1742-2094-7-52
43. Jarius, S., & Wildemann, B. (2011). An early case of neuromyelitis optica: On a forgotten report by Jacob Lockhart Clarke, FRS. Multiple Sclerosis Journal, 17(11), 1384–1386. https://doi.org/10.1177/1352458511413809
44. Jeyalatha, M. V., Therese, K. L., & Anand, A. R. (2022). An update on the laboratory diagnosis of neuromyelitis optica spectrum disorders. Journal of Clinical Neurology, 18(2), 152–163. https://doi.org/10.3988/jcn.2022.18.2.152
45. Kang, Y.-R., Kim, K. H., Hyun, J.-W., Kim, S. H., & Kim, H. J. (2024). Efficacy of tocilizumab in highly relapsing MOGAD with an inadequate response to intravenous immunoglobulin therapy: A case series. Multiple Sclerosis and Related Disorders, 91, Article 105859. https://doi.org/10.1016/j.msard.2024.105859
46. Kessler, R. A., Mealy, M. A., & Levy, M. (2016). Treatment of neuromyelitis optica spectrum disorder: Acute, preventive, and symptomatic. Current Treatment Options in Neurology, 18(1), Article 2. https://doi.org/10.1007/s11940-015-0387-9
47. Kim, S. H., Park, N. Y., Kim, K. H., Kim, Y., Jung, J. Y., & Kim, H. J. (2022). Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: A 14-year real-life experience. Neurology: Neuroimmunology & Neuroinflammation, 9(5), Article e1179. https://doi.org/10.1212/NXI.0000000000001179
48. Kim, W., & Kim, H. J. (2023). An update on biologic treatments for neuromyelitis optica spectrum disorder. Expert Review of Clinical Immunology, 19(1), 111–121. https://doi.org/10.1080/1744666X.2023.2144833
49. Kleiter, I., Gahlen, A., Borisow, N., Fischer, K., Wernecke, K. D., Hellwig, K., Paciello, G., Ruprecht, K., Havla, J., Kümpfel, T., Aktas, O., Ringelstein, M., Geis, C., Kleinschnitz, C., Berthele, A., Hemmer, B., Angstwurm, K., Tumani, H., Fassbender, K., … NEMOS (Neuromyelitis Optica Study Group). (2018). Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurology: Neuroimmunology & Neuroinflammation, 5(6), Article e504. https://doi.org/10.1212/NXI.0000000000000504
50. Kümpfel, T., Giglhuber, K., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Berthele, A., Havla, J., Hellwig, K., Hümmert, M. W., Jarius, S., Kleiter, I., Klotz, L., Korporal-Kuhnke, M., Krumbholz, M., Ringelstein, M., Ruprecht, K., Senel, M., Stellmann, J. P., Trebst, C., … NEMOS (Neuromyelitis Optica Study Group). (2024). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)—Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology, 271(1), 141–176. https://doi.org/10.1007/s00415-023-11910-f
51. Ladha, P., Amatya, S., Kagzi, Y., & Levy, M. (2025). Pregnancy outcomes in neuromyelitis optica spectrum disorder: A meta-analysis of pharmacotherapeutic agents. Neurology, 104(7 Suppl 1), Article 2004. https://doi.org/10.1212/WNL.0000000000203004
52. Lai, Q.-L., Zhang, Y.-X., Cai, M.-T., Zheng, Y., & Shen, C.-H. (2021). Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody–associated disease: A systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders, 14, 1–14. https://doi.org/10.1177/17562864211045860
53. Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005). IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. The Journal of Experimental Medicine, 202(4), 473–477. https://doi.org/10.1084/jem.20050304
54. Levy, M., Flanagan, E. P., Kümpfel, T., Marignier, R., Palace, J., & Fujihara, K. (2026). Safety and efficacy of satralizumab in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Results from the phase 3 METEOROID trial. Neurology, 106(3), Article 6020. https://doi.org/10.1212/WNL.0000000000204000
55. Li, R., Li, C., Huang, Q., Zhang, Y., & Lu, Z. (2022). Immunosuppressant and neuromyelitis optica spectrum disorder: Optimal treatment duration and risk of discontinuation. European Journal of Neurology, 29(9), 2792–2800. https://doi.org/10.1111/ene.15406
56. Li, X., Xue, B., Li, J., & Wang, Y. (2025). High-efficacy treatment in neuromyelitis optica spectrum disorder patients with seropositive AQP4 antibodies—A real-world study. Annals of Clinical and Translational Neurology, 12(10), 1983–1991. https://doi.org/10.1002/acn3.52189
57. Lucchinetti, C. F., Guo, Y., Popescu, B. F., Fujihara, K., Itoyama, Y., & Misu, T. (2014). The pathology of an autoimmune astrocytopathy: Lessons learned from neuromyelitis optica. Brain Pathology, 24(1), 83–97. https://doi.org/10.1111/bpa.12099
58. Malaysian Society of Infectious Diseases and Chemotherapy. (2023). Adult immunisation guidelines (3rd ed.). https://adultimmunisation.msidc.my/wp-content/uploads/2023/11/AIG-3rd-edition-2023.pdf
59. Marignier, R., Pittock, S. J., Paul, F., Kim, H. J., Bennett, J. L., Weinshenker, B. G., Wingerchuk, D. M., Fujihara, K., Cutter, G. R., Aktas, O., Hartung, H. P., Lublin, F. D., Drappa, J., Barron, G., Madani, S., Ratchford, J. N., & Cree, B. A. C. (2022). AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 57, Article 103356. https://doi.org/10.1016/j.msard.2021.103356
60. Montalban, X., Lebrun-Frénay, C., Oh, J., Calabresi, P. A., Cohen, J. A., Tintoré, M., & Miller, D. H. (2025). Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. The Lancet Neurology, 24(10), 850–865. https://doi.org/10.1016/S1474-4422(25)00210-2
61. Musubire, A.K., Derdelinckx, J., Reynders, T., Van Hecke, W., & Ssebuwufu, R. (2021). Neuromyelitis optica spectrum disorders in Africa. Neurology: Neuroimmunology & Neuroinflammation, 8(6), Article e1089. https://doi.org/10.1212/NXI.0000000000001089
62. Nepal, G., Kharel, S., Coghlan, M. A., Ojha, R., & Reindl, M. (2022). Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis. Journal of Neuroimmunology, 364, Article 577812. https://doi.org/10.1016/j.jneuroim.2022.577812
63. Novi, G., Bovis, F., Sciolla, C., & Inglese, M. (2025). Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder: A 5-year observational study. CNS Drugs, 39(7), 693–705. https://doi.org/10.10007/s40263-025-01180-2
64. Oertel, F. C., Zimmermann, H., Paul, F., & Brandt, A. U. (2017). Optical coherence tomography in neuromyelitis optica spectrum disorders: Potential advantages for individualised monitoring of progression and therapy. EPMA Journal, 9(1), 21–33. https://doi.org/10.1007/s13167-017-0122-3
65. Okuda, D. T., Moog, T. M., McCreary, M., & Contentti, E. C. (2023). Treatment transitions in neuromyelitis optica spectrum disorder increase risk for disease advancement. Multiple Sclerosis and Related Disorders, 79, Article 105041. https://doi.org/10.1016/j.msard.2023.105041
66. Ongphichetmetha, T., Jitprapaikulsan, J., Siritho, S., & Prayoonwiwat, N. (2024). Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder. Scientific Reports, 14(1), Article 3503. https://doi.org/10.1038/s41598-024-54012-1
67. Palace, J., Wingerchuk, D. M., Fujihara, K., Pittock, S. J., Berthele, A., Weinshenker, B. G., & Levy, M. (2021). Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Multiple Sclerosis and Related Disorders, 47, Article 102641. https://doi.org/10.1016/j.msard.2020.102641
68. Papp, V., Magyari, M., Aktas, O., Berger, T., Broadley, S. A., Cabre, P., Jacob, A., Marignier, R., & Illes, Z. (2021). Worldwide incidence and prevalence of neuromyelitis optica: A systematic review. Neurology, 96(2), 59–77. https://doi.org/10.1212/WNL.000000000011153
69. Paul, F., Marignier, R., Palace, J., Fujihara, K., Kim, H. J., Bennett, J. L., & Wingerchuk, D. M. (2023). International Delphi consensus on the management of AQP4-IgG+ NMOSD: Recommendations for eculizumab, inebilizumab, and satralizumab. Neurology: Neuroimmunology & Neuroinflammation, 10(4), Article e200124. https://doi.org/10.1212/NXI.0000000000200124
70. Pittock, S. J., Barnett, M., Bennett, J. L., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J., Weinshenker, B. G., & Wingerchuk, D. M. (2023). Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Annals of Neurology, 93(6), 1053–1068. https://doi.org/10.1002/ana.26626
71. Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J., Nakashima, I., Terzi, M., Totolici, C., Viswanathan, S., Weinshenker, B. G., & Wingerchuk, D. M. (2019). Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. The New England Journal of Medicine, 381(7), 614–625. https://doi.org/10.1056/NEJMoa1900868
72. Prasad, M. (2024). Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clinical Epidemiology and Global Health, 25, Article 101484. https://doi.org/10.1016/j.cegh.2023.101484
73. Ramirez, A. D., & Romero, R. (2024). Eculizumab therapy in a seronegative patient with NMOSD: A case report. Neurology, 102(7 Suppl 1), Article 3707. https://doi.org/10.1212/WNL.0000000000202890
74. Redenbaugh, V., Fryer, J. P., Cacciaguerra, L., Flanagan, E. P., & Pittock, S. J. (2024). Diagnostic utility of MOG antibody testing in cerebrospinal fluid. Annals of Neurology, 96(1), 34–45. https://doi.org/10.1002/ana.26912
75. Ringelstein, M., Ayzenberg, I., Lindenblatt, G., Fischer, K., Lensch, E., & Kleiter, I. (2022). Interleukin-6 receptor blockade in treatment-refractory MOG-IgG–associated disease and neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology & Neuroinflammation, 9(1), Article e1100. https://doi.org/10.1212/NXI.0000000000001100
76. Rommer, P. S., Jiang, W., Nolte, J. P., & Paul, F. (2026). Complement inhibition for acute neuromyelitis optica spectrum disorder attacks: Insights from an international case series. Neurology: Neuroimmunology & Neuroinflammation, 13(2), Article e200548. https://doi.org/10.1212/NXI.0000000000200548
77. Satukijchai, C., Mariano, R., Messina, S., Sa, M., Woodhall, M. R., & Palace, J. (2022). Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody–associated disease in the United Kingdom. JAMA Network Open, 5(1), Article e2142780. https://doi.org/10.1001/jamanetworkopen.2021.42780
78. Schindler, P., Aktas, O., Ringelstein, M., & Paul, F. (2023). Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: A current review. Expert Review of Clinical Immunology, 19(1), 71–91. https://doi.org/10.1080/1744666X.2023.2144832
79. Sen, S., Tuncer, A., Terzi, M., & Fujihara, K. (2023). Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment. Multiple Sclerosis and Related Disorders, 79, Article 104949. https://doi.org/10.1016/j.msard.2023.104949
80. Solomon, A. J., Marrie, R. A., Viswanathan, S., & Cohen, J. A. (2023). Global barriers to the diagnosis of multiple sclerosis: Data from the Multiple Sclerosis International Federation Atlas of MS, third edition. Neurology, 101(6), e624–e635. https://doi.org/10.1212/WNL.0000000000207450
81. Solomon, J. M., Paul, F., Chien, C., Bellmann-Strobl, J., & Ruprecht, K. (2021). A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Therapeutic Advances in Neurological Disorders, 14, 1–21. https://doi.org/10.1177/17562864211014389
82. Songwisit, S., Kosiyakul, P., Jitprapaikulsan, J., & Siritho, S. (2020). Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. Scientific Reports, 10(1), Article 16727. https://doi.org/10.1038/s41598-020-73892-7
83. Tahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, H., & Fujihara, K. (2020). Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 19(4), 298–306. https://doi.org/10.1016/S1474-4422(20)30066-1
84. Tan, K., Yeo, T., Yong, K. P., & Quek, A. M. (2021). Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore—Epidemiology and evolution of an emerging subspecialty. Neurology and Clinical Neuroscience, 9(4), 259–265. https://doi.org/10.1111/ncn3.12502
85. Tian, D.-C., Li, Z., Yuan, M., Zhang, C., Shi, F. D., & Wang, Y. (2020). Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based study. The Lancet Regional Health—Western Pacific, 2, Article 100021. https://doi.org/10.1016/j.lanwpc.2020.100021
86. Tisavipat, N., Jitpratoom, P., Siritho, S., & Prayoonwiwat, N. (2022). Epidemiology and burden of NMOSD, MS, and MOGAD in Thailand: A population-based study. Neurology, 99(23 Suppl 2), Article S34. https://doi.org/10.1212/WNL.0000000000201850
87. Tkachuk, V., Balbuena Aguirre, M. E., Alonso, R., Villa, A., & Carnero Contentti, E. (2023). Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort. Multiple Sclerosis and Related Disorders, 70, Article 104485. https://doi.org/10.1016/j.msard.2022.104485
88. Tommaso, G., Damiano, P., & Pietro, I. (2025). Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report. Multiple Sclerosis Journal, 31(5), 615–617. https://doi.org/10.1177/13524585241295000
89. Traboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., & Yamamura, T. (2020). Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomised, double-blind, multicentre, placebo-controlled phase 3 trial. The Lancet Neurology, 19(5), 402–412. https://doi.org/10.1016/S1474-4422(20)30078-8
90. Vishnevetsky, A., Kaplan, T. B., & Levy, M. (2022). Transitioning immunotherapy in neuromyelitis optica spectrum disorder—When and how to switch. Expert Opinion on Biological Therapy, 22(11), 1393–1404. https://doi.org/10.1080/14712598.2022.2113870
91. Viswanathan, S., Wong, A. H., Quek, A. M., & Yuki, N. (2015). Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. Journal of Neuroimmunology, 282, 92–96. https://doi.org/10.1016/j.jneuroim.2015.03.021
92. Viswanathan, S., & Wah, L. M. (2019). A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. Multiple Sclerosis Journal, 25(11), 1452–1461. https://doi.org/10.1177/1352458518792429
93. Wang, L., Liu, K., Tan, X., & Zhang, C. (2020). Remedial effect of intravenous cyclophosphamide in corticosteroid-refractory patients in the acute phase of neuromyelitis optica spectrum disorder-related optic neuritis. Frontiers in Neurology, 11, Article 612097. https://doi.org/10.3389/fneur.2020.612097
94. Wang, Y., Zhao, M., Yao, M., & Qiu, W. (2023). Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety. Multiple Sclerosis and Related Disorders, 80, Article 105062. https://doi.org/10.1016/j.msard.2023.105062
95. Whittam, D. H., Karthikeayan, V., Gibbons, E., Kneen, R., & Jacob, A. (2020). Treatment of MOG antibody associated disorders: Results of an international survey. Journal of Neurology, 267(12), 3565–3577. https://doi.org/10.10007/s00415-020-10026-x
96. Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., Jarius, S., Lana-Peixoto, M., Levy, M., Simon, J. H., Tenembaum, S., Traboulsee, A. L., Waters, P., Wellik, K. E., & Weinshenker, B. G. (2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2), 177–189. https://doi.org/10.1212/WNL.0000000000001729
97. Wingerchuk, D. M., Fujihara, K., Palace, J., Berthele, A., Levy, M., Kim, H. J., Weinshenker, B. G., & Pittock, S. J. (2021). Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Annals of Neurology, 89(6), 1088–1098. https://doi.org/10.1002/ana.26049
98. Wingerchuk, D. M., Hogancamp, W. F., O'Brien, P. C., & Weinshenker, B. G. (1999). The clinical course of neuromyelitis optica (Devic's syndrome). Neurology, 53(5), 1107–1114. https://doi.org/10.1212/wnl.53.5.1107
99. Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007). The spectrum of neuromyelitis optica. The Lancet Neurology, 6(9), 805–815. https://doi.org/10.1016/S1474-4422(07)70216-8
100. Wingerchuk, D. M., Marignier, R., Palace, J., Fujihara, K., Bennett, J. L., & Paul, F. (2025, September). IPND 2025: Revised consensus criteria, classification, and nomenclature for neuromyelitis optica spectrum disorders (Late-Breaking Abstract P427) [Conference presentation]. ECTRIMS Congress.
101. Wu, Y., Geraldes, R., Juryńczyk, M., Palace, J., & Leite, M. I. (2023). Double-negative neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 29(11–12), 1353–1362. https://doi.org/10.1177/13524585231189400
102. Yamamura, T., Kleiter, I., Fujihara, K., Palace, J., Greenberg, B., Zakrzewska-Pniewska, B., Patti, F., Tsai, C. P., Saiz, A., Yamazaki, H., Kawata, Y., Wright, P., & DeSeze, J. (2019). Trial of satralizumab in neuromyelitis optica spectrum disorder. The New England Journal of Medicine, 381(22), 2114–2124. https://doi.org/10.1056/NEJMoa1901547
103. Yin, Z., Qiu, Y., Duan, A., & Zhou, L. (2023). Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: A Bayesian network meta-analysis. Journal of Neurology, 270(6), 2950–2963. https://doi.org/10.1007/s00415-023-11608-2
104. Zammar, K., Safan, A., Abushalbak, D. J., & Levy, M. (2026). Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: Systematic review and meta-analysis. Journal of Neuroimmunology, 417, Article 578945. https://doi.org/10.1016/j.jneuroim.2025.578945
105. Zhang, C., Zhang, M., Qiu, W., Ma, H., Zhang, X., Zhu, Z., Yang, C. S., Jia, D., Zhang, T. X., Yuan, M., Zhang, C., & Lu, Z. (2020). Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): An open-label, multicentre, randomised, phase 2 trial. The Lancet Neurology, 19(5), 391–401. https://doi.org/10.1016/S1474-4422(20)30070-3
106. Zhou, J., Yang, X., Wang, X., & Zhang, Y. (2025). Immunotherapy for neuromyelitis optica spectrum disorder: A comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. Frontiers in Neurology, 16, Article 1559118. https://doi.org/10.3389/fneur.2025.1559118